Drug
CD 2027
CD 2027: highest development phase Phase 2, developed by Galderma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Galderma
Trials
| Drug | Phase | Indication |
|---|---|---|
| CD 2027 NCT00763503 | Phase 2 | Plaque-type Psoriasis |
Latest
No recent events.
Follow CD 2027 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.